0001209191-17-032901.txt : 20170516 0001209191-17-032901.hdr.sgml : 20170516 20170516211758 ACCESSION NUMBER: 0001209191-17-032901 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170516 FILED AS OF DATE: 20170516 DATE AS OF CHANGE: 20170516 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 79 T.W. ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: P. O. BOX # 110341 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moses Jennifer K. CENTRAL INDEX KEY: 0001706667 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 17850174 MAIL ADDRESS: STREET 1: 79 TW ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2017-05-16 0 0001560241 G1 Therapeutics, Inc. GTHX 0001706667 Moses Jennifer K. C/O G1 THERAPEUTICS, INC. 79 T.W. ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 0 1 0 0 VP of Finance & Admin Stock Option (Right to Buy) 0.39 2023-12-05 Common Stock 4000 D Stock Option (Right to Buy) 0.39 2024-07-11 Common Stock 6666 D Stock Option (Right to Buy) 0.30 2024-02-27 Common Stock 33333 D Stock Option (Right to Buy) 3.72 2025-12-21 Common Stock 14333 D Stock Option (Right to Buy) 4.19 2026-05-10 Common Stock 60000 D All shares underlying this option have vested. The number of underlying shares of common stock and the exercise price reported reflect a 1-for-3 reverse stock split of the Issuer's common stock effected on May 11, 2017. The shares underlying this option vest as to 25% of the shares on February 28, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The shares underlying this option vest as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. The shares underlying this option vest as to 25% of the shares on May 10, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. Exhibit 24.1 - Power of Attorney /s/ Caroline G. Gammill, attorney-in-fact 2017-05-16 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

EXHIBIT 24.1
POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints Anne Leland, Brenda Meyette, Jacquelyn Cannata, Caroline Gammill, John
Condon, Nishant Dharia and Brian Shea of Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C., and Gregory Mossinghoff of G1 Therapeutics, Inc. signing singly,
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
	(1)	execute for and on behalf of the undersigned, forms and authentication
documents for EDGAR Filing Access;

(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such forms and
authentication documents;

(3) 	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or 10% shareholder of the Company, Forms 3, 4 and 5
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

	(4)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5
and timely file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and

	(5)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact, on behalf of
the undersigned pursuant to this Power of Attorney, shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 11th  day of May, 2017.

					/s/ Jennifer K. Moses
					 Jennifer K. Moses